Lowering of maximum urethral pressure by (D-Met2, Pro5)-enkephalinamide in patients with neurogenic vesicourethral dysfunction due to spinal cord injury.
The effect of (D-Met2, Pro5)-enkephalinamide upon urethra in patients with chronic neurogenic vesicourethral dysfunction due to spinal cord injury was investigated. Urethral pressure profile was recorded with Urolab 1154 and 1700A urethral pressure profile puller-pump. Ten mg of the drug was administered subcutaneously. Urethral pressure profile was again recorded at 10, 20, 30, 40, 50 and 60 min after drug administration. Heart rate was also noted at these time points. There was a significant decrease in maximum urethral pressure from 134 +/- 19 cm H2O in the basal study to 107 +/- 28 cm H2O at 10 min (p less than 0.01); 102 +/- 30 cm H2O at 20 min (p less than 0.001); 94 +/- 19 cm H2O at 30 min (p less than 0.001); 100 +/- 20 cm H2O at 40 min (p less than 0.001); 102 +/- 29 cm H2O at 50 min (p less than 0.001); and 109 +/- 36 cm H2O at 60 min (p less than 0.001) after subcutaneous administration of (D-Met2, Pro5)-enkephalinamide. There was a significant increase in heart rate from 81 +/- 5 to 95 +/- 9 at 10 min (p less than 0.01) and to 87 +/- 10 at 20 min (p less than 0.01) after the drug. Subsequenly, the heart rate returned to near-basal values. The side effects were: conjunctival injection in all the cases; dryness of mouth in two; itching over the body in one; sensation of insect crawling over the body in one; and feeling of oppression over the chest immediately after drug administration in one.(ABSTRACT TRUNCATED AT 250 WORDS)